Investor Center Bellicum Announces Clinical Presentations on Lead Product Candidate BPX-501 at the 23rd Congress of the European Hematology Association Read more about Bellicum Announces Clinical Presentations on Lead Product Candidate BPX-501 at the 23rd Congress of the European Hematology Association Bellicum Announces Oral Presentation on Dual-Switch CAR-T Technology at the 21st Annual Meeting of the American Society of Gene and Cell Therapy Read more about Bellicum Announces Oral Presentation on Dual-Switch CAR-T Technology at the 21st Annual Meeting of the American Society of Gene and Cell Therapy Bellicum Pharmaceuticals Reports First Quarter 2018 Financial Results Read more about Bellicum Pharmaceuticals Reports First Quarter 2018 Financial Results Bellicum Pharmaceuticals Announces Closing of Public Offering Read more about Bellicum Pharmaceuticals Announces Closing of Public Offering Bellicum Pharmaceuticals Announces Pricing of Public Offering of Common Stock Read more about Bellicum Pharmaceuticals Announces Pricing of Public Offering of Common Stock Bellicum Pharmaceuticals Announces Proposed Public Offering of Common Stock Read more about Bellicum Pharmaceuticals Announces Proposed Public Offering of Common Stock Bellicum Announces Clinical Hold Lifted on U.S. Studies of BPX-501 Read more about Bellicum Announces Clinical Hold Lifted on U.S. Studies of BPX-501 Bellicum Pharmaceuticals Provides Operational Update and Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2017 Read more about Bellicum Pharmaceuticals Provides Operational Update and Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2017 Bellicum Announces Interim Results Showing Low Rates of Cancer Recurrence in Pediatric AML Patients Treated with BPX-501 Read more about Bellicum Announces Interim Results Showing Low Rates of Cancer Recurrence in Pediatric AML Patients Treated with BPX-501 Bellicum Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call and Webcast on March 13, 2018 Read more about Bellicum Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call and Webcast on March 13, 2018 Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page Next › Last page Last » Subscribe to
Bellicum Announces Clinical Presentations on Lead Product Candidate BPX-501 at the 23rd Congress of the European Hematology Association Read more about Bellicum Announces Clinical Presentations on Lead Product Candidate BPX-501 at the 23rd Congress of the European Hematology Association
Bellicum Announces Oral Presentation on Dual-Switch CAR-T Technology at the 21st Annual Meeting of the American Society of Gene and Cell Therapy Read more about Bellicum Announces Oral Presentation on Dual-Switch CAR-T Technology at the 21st Annual Meeting of the American Society of Gene and Cell Therapy
Bellicum Pharmaceuticals Reports First Quarter 2018 Financial Results Read more about Bellicum Pharmaceuticals Reports First Quarter 2018 Financial Results
Bellicum Pharmaceuticals Announces Closing of Public Offering Read more about Bellicum Pharmaceuticals Announces Closing of Public Offering
Bellicum Pharmaceuticals Announces Pricing of Public Offering of Common Stock Read more about Bellicum Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Bellicum Pharmaceuticals Announces Proposed Public Offering of Common Stock Read more about Bellicum Pharmaceuticals Announces Proposed Public Offering of Common Stock
Bellicum Announces Clinical Hold Lifted on U.S. Studies of BPX-501 Read more about Bellicum Announces Clinical Hold Lifted on U.S. Studies of BPX-501
Bellicum Pharmaceuticals Provides Operational Update and Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2017 Read more about Bellicum Pharmaceuticals Provides Operational Update and Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2017
Bellicum Announces Interim Results Showing Low Rates of Cancer Recurrence in Pediatric AML Patients Treated with BPX-501 Read more about Bellicum Announces Interim Results Showing Low Rates of Cancer Recurrence in Pediatric AML Patients Treated with BPX-501
Bellicum Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call and Webcast on March 13, 2018 Read more about Bellicum Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call and Webcast on March 13, 2018
